KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Ratio: 2009-2025

Historic Equity Ratio for Neogenomics (NEO) over the last 14 years, with Sep 2025 value amounting to 0.61.

  • Neogenomics' Equity Ratio rose 10.18% to 0.61 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.61, marking a year-over-year increase of 10.18%. This contributed to the annual value of 0.55 for FY2024, which is 1.64% down from last year.
  • Latest data reveals that Neogenomics reported Equity Ratio of 0.61 as of Q3 2025, which was down 0.48% from 0.61 recorded in Q2 2025.
  • Neogenomics' 5-year Equity Ratio high stood at 0.61 for Q2 2025, and its period low was 0.55 during Q4 2024.
  • In the last 3 years, Neogenomics' Equity Ratio had a median value of 0.56 in 2024 and averaged 0.57.
  • Per our database at Business Quant, Neogenomics' Equity Ratio tumbled by 97.47% in 2021 and then grew by 10.18% in 2025.
  • Quarterly analysis of 5 years shows Neogenomics' Equity Ratio stood at 0.59 in 2021, then dropped by 3.23% to 0.57 in 2022, then fell by 2.36% to 0.56 in 2023, then dropped by 1.64% to 0.55 in 2024, then increased by 10.18% to 0.61 in 2025.
  • Its last three reported values are 0.61 in Q3 2025, 0.61 for Q2 2025, and 0.55 during Q1 2025.